RIFATER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rifater, and what generic alternatives are available?
Rifater is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in RIFATER is isoniazid; pyrazinamide; rifampin. There are five drug master file entries for this compound. Additional details are available on the isoniazid; pyrazinamide; rifampin profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RIFATER?
- What are the global sales for RIFATER?
- What is Average Wholesale Price for RIFATER?
Summary for RIFATER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 8 |
| Clinical Trials: | 2 |
| Drug Prices: | Drug price information for RIFATER |
| DailyMed Link: | RIFATER at DailyMed |
Recent Clinical Trials for RIFATER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Phillip Low | Phase 3 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Phase 3 |
| Vanderbilt University | Phase 3 |
US Patents and Regulatory Information for RIFATER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | RIFATER | isoniazid; pyrazinamide; rifampin | TABLET;ORAL | 050705-001 | May 31, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
